Today: 13 May 2026
Browse Category

NASDAQ:CLRB 5 May 2026

Cellectar Biosciences Stock: $140 Million Deal Puts Iopofosine FDA Filing in Focus

Cellectar Biosciences Stock: $140 Million Deal Puts Iopofosine FDA Filing in Focus

Cellectar Biosciences secured up to $140 million in new financing and reported a 83.6% overall response rate for iopofosine I 131 in a Phase 2b study for Waldenström macroglobulinemia. The company’s cash had fallen to $13.2 million at the end of 2025, raising doubts about its ability to continue. Shares traded heavily, with volume surging to 53.78 million. Cellectar plans a confirmatory trial and possible FDA filing.
5 May 2026
·

Stock Market Today

  • NetApp (NTAP) Valuation: Undervalued Despite Recent Share Price Gains
    May 13, 2026, 2:35 PM EDT. NetApp's (NTAP) stock has gained 21.2% over the past month and 19.0% over the last year, driven by demand in data storage, cloud infrastructure, and AI. Yet, a Discounted Cash Flow (DCF) analysis by Simply Wall St shows the stock is undervalued by approximately 35%, with an intrinsic value estimated at $179.04 versus the current price near $116. Recent Free Cash Flow projections indicate growth to $2.56 billion by 2035. The 5/6 valuation score signals more insights are needed, highlighting that despite recent gains, NetApp may still present value opportunities for investors focused on cash flow fundamentals.

Latest articles

Palantir Stock Slides as Zelenskiy Meeting Puts War-AI Bet in Focus

Palantir Stock Slides as Zelenskiy Meeting Puts War-AI Bet in Focus

13 May 2026
Palantir shares fell 4.4% to $129.97 Wednesday as CEO Alex Karp met President Volodymyr Zelenskiy in Kyiv to discuss expanding AI use in Ukraine’s war effort. Kyiv’s Brave1 Dataroom project, launched with Palantir, is training AI models to intercept Russian drones. Russia fired at least 800 drones at Ukraine on Wednesday, killing six. Palantir’s U.S. government and commercial revenue surged in the first quarter.
Why Grab Holdings Stock Is Back Under Pressure After a Big Q1 Beat

Why Grab Holdings Stock Is Back Under Pressure After a Big Q1 Beat

13 May 2026
Grab shares fell 1.1% to $3.60 in New York after first-quarter revenue beat estimates, rising 24% to $955 million. Profit jumped to $120 million from $10 million a year earlier. Investors weighed strong results against Indonesia’s new 8% ride-hailing commission cap. Grab kept its 2026 revenue and adjusted EBITDA outlook unchanged.
SoFi Bought a Key IPO Access Tool. The Stock Is Still Telling a More Cautious Story

SoFi Bought a Key IPO Access Tool. The Stock Is Still Telling a More Cautious Story

13 May 2026
SoFi acquired PrimaryBid’s technology to expand IPO access for retail investors, confirmed by both companies. SoFi shares fell 2.9% to $15.44 after Truist cut its price target, citing concerns over loan and technology platforms. The acquisition follows a drop in technology-platform accounts and comes as SoFi reported strong first-quarter revenue and member growth. Terms of the deal were not disclosed.

Popular

Cerebras IPO Frenzy Tests Wall Street’s $50 Billion AI Chip Bet

Cerebras IPO Frenzy Tests Wall Street’s $50 Billion AI Chip Bet

13 May 2026
Cerebras Systems is set to price its IPO above the $150–$160 per share range, Bloomberg reported, with orders more than 20 times available shares, according to Reuters. The company will offer 30 million shares and begin trading Thursday on Nasdaq under the ticker CBRS. Morningstar estimates the revised range could value Cerebras near $50 billion. Cerebras reported over $500 million in revenue last year but remains unprofitable.
Go toTop